Eosinophilic Esophagitis Market

DelveInsight’s ‘Eosinophilic Esophagitis (EoE)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The EoE market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted EoE market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current EoE treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Eosinophilic Esophagitis: Disease Understanding and Treatment Algorithm

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is defined as a chronic, local immune-mediated esophageal disease, clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The major symptoms include heartburn, regurgitation, and esophageal stenosis, and dysphagia, more frequent in young adults and children.


The disease was first described in 1978 and misinterpreted as achalasia. In the early 1980s, esophageal eosinophilia’s importance was perceived and was considered a diagnostic criterion for reflux disease. It took more than a decade before EoE was described in two case series and recognized as a distinct disease entity characterized by symptoms of esophageal dysfunction and eosinophil infiltration.


Established risk factors are male gender, Caucasian race, and atopy. Increased risk amongst family members and a single nucleotide polymorphism (SNP) in a gene coding thymic stromal lymphopoietin (TSLP) on the pseudoautosomal region of the X and Y chromosomes supports a genetic predisposition. Environmental factors including the timing and nature of food and aeroallergen exposure to the developing immune system. The pathophysiology of EoE is complex, with a network of various cells and molecules contributing to it, especially eosinophils, Th2 cells, TSLP, TGF-β1, and IL-13. Molecules that have not yet been identified may contribute to the mechanism of EoE.


The diagnosis of EoE depends on the clinical manifestations and endoscopic and histological findings in esophageal mucosa biopsies. Endoscopic findings in most patients include linear grooves on the esophagus wall, concentric rings, whitish exudates that resemble candidal infection, Schatzki rings, a reduction in the size of the esophagus, and superficial tears of the mucosa after endoscope introduction. A histological diagnosis is confirmed when there are ≥ 15 eosinophils per high-power field (HPF).


The Food and Drug Administration currently approves no drugs for the treatment of EoE. The therapeutic approach consists of the “3D” concept: diet, drugs, and dilation. The patient is treated based on the severity of their symptoms or endoscopic findings, such as esophageal narrowing or stricture. Histological improvement is usually used as the primary outcome in clinical trials rather than symptomatic improvement due to the difficulty in evaluating the symptoms objectively and uniformly. It is common for these patients to modify the patient’s dietary or eating behavior to avoid dysphagia or an impaction. PPIs are useful as a first-line treatment for patients with EoE. Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission. Esophageal endoscopic dilation is most commonly used in adults with established esophageal strictures. According to recent EoE consensus statements and societal guidelines, periodic dilation is now considered an acceptable alternative to medical or dietary therapy in some healthy adults with EoE.


Eosinophilic Esophagitis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Eosinophilic Esophagitis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Eosinophilic Esophagitis market report gives a thorough understanding of Eosinophilic Esophagitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Eosinophilic Esophagitis in the US, Europe, and Japan.

Eosinophilic Esophagitis Epidemiology

The Eosinophilic Esophagitis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical and forecasted Eosinophilic Esophagitis epidemiology segmented as the Diagnosed prevalent cases of Eosinophilic Esophagitis, Gender-specific Cases of Eosinophilic Esophagitis and Age-specific Cases of Eosinophilic Esophagitis The report includes the prevalent scenario of Eosinophilic Esophagitis symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Eosinophilic Esophagitis Epidemiology

The epidemiology segment also provides the Eosinophilic Esophagitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The diagnosed prevalent population of Eosinophilic Esophagitis in the 7MM countries was estimated to be 547,924 cases in 2020.

Eosinophilic Esophagitis Drug Chapters

The drug chapter segment of the Eosinophilic Esophagitis report encloses the detailed analysis of Eosinophilic Esophagitis marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Eosinophilic Esophagitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


During the past 2 decades, EoE has emerged as a dominant cause of dysphagia worldwide. There are currently no drugs approved by the Food and Drug Administration for the treatment of EoE. Treatment strategies available for EoE fall into three categories: avoidance of triggers through dietary modification, pharmacologic therapy (predominantly corticosteroids), and mechanical dilation of the esophagus. PPIs are useful as a first-line treatment for patients with EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission. The use of novel targeted biologic therapies for EoE is actively evaluated. There is a need for uniform endpoints in clinical trials to facilitate meaningful comparisons between therapies. Furthermore, a deeper understanding of the natural history of EoE in both children and adults is needed to inform clinical decisions regarding the optimal use of disease monitoring and long-term maintenance therapy.

Products detail in the report…


Eosinophilic Esophagitis Emerging Drugs


Budesonide Oral Suspension (Takeda/Shire) is a topically active, oral viscous formulation of budesonide, formulated specifically as an investigational treatment for EoE. In an open-label clinical trial, orally administered viscous budesonide was more effective than nebulized or swallowed budesonide for improving esophageal eosinophil counts and endoscopic findings in adults with a new diagnosis of EoE. The US FDA has granted priority review, breakthrough therapy designation, and orphan designation to BOS for the treatment of EoE. The company recently submitted a new drug application (NDA) based on data from the pivotal Phase III trials ORBIT1 and ORBIT2. Furthermore, the company is conducting a Phase III continuation study with BOS for adolescent and adult subjects with EoE.


Cendakimab (Bristol-Myers Squibb) is a recombinant humanized, high affinity, selective, anti–interleukin-13 (IL-13) monoclonal antibody. RPC4046 binds an IL-13 epitope that prevents its binding to both interleukin-13 receptor (IL-13R) (alpha) 1 and IL-13R (alpha) 2, providing potential advantages in efficacy and/or safety. The drug has been granted orphan drug designation for the treatment of EoE. In the Phase II study, RPC4046 demonstrated positive results, and currently, the company is conducting a Phase III clinical study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.

Products detail in the report…

Eosinophilic Esophagitis Market Outlook

The Eosinophilic Esophagitis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted EoE market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Eosinophilic Esophagitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Eosinophilic Esophagitis market in the 7MM is expected to change in the study period 2018–2030.


Currently, the 3 “D”s (“Drugs, Diet, and Dilation”) are considered the fundamental components of treatment. The first two components, which involve the use of proton pump inhibitors, corticosteroids, immunosuppressants, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases, whereas endoscopic dilation is reserved for esophageal strictures. Herein, the most important aspects of eosinophilic Esophagitis pathophysiology will be reviewed, in addition to evidence for the various treatments. There are currently no drugs approved by the Food and Drug Administration for the treatment of EoE.


Key Findings

This section includes a glimpse of the Eosinophilic Esophagitis market in the 7MM. The market size of Eosinophilic Esophagitis in the seven major markets was found to be USD 430.9 million in 2020.


The United States: Market Outlook

This section provides the total Eosinophilic Esophagitis market size and market size by therapies of Eosinophilic Esophagitis in the United States.


The United States accounts for the highest market size of Eosinophilic Esophagitis in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


PPIs are useful as a first-line treatment for patients with EoE. Initial PPI doses of 20-40 mg or 1 mg/kg per dose are given twice daily in adults and children, respectively. The reported response rates to PPI therapy in the EoE population can vary widely from 30–70%. This is likely due to distinct clinical scenarios but there are currently no clinical features that discern a patient who will respond to PPI monotherapy.


Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.


Bougie and balloon dilation is the only endoscopic treatment available for EoE. It is performed in patients with persistent dysphagia resistant to medical treatment in whom remission of inflammation has been achieved and in patients with severe dysphagia and a history of food impaction.


EU-5 Countries: Market Outlook

The total Eosinophilic Esophagitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.


Japan Market Outlook

The total Eosinophilic Esophagitis market size and market size by therapies of Eosinophilic Esophagitis in Japan are also mentioned.

Eosinophilic Esophagitis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Eosinophilic Esophagitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Eosinophilic Esophagitis key players involved in developing targeted therapeutics.


Major players include Budesonide Oral Suspension (Takeda), Dupilumab (Regeneron Pharmaceuticals/Sanofi), Cendakimab (Bristol-Myers Squibb), APT-1011 (Ellodi Pharmaceuticals), Benralizumab (AstraZeneca), Lirentelimab (Allakos) whose key products are expected to get launched in the US market by 20XX.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Eosinophilic Esophagitis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Eosinophilic Esophagitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Eosinophilic Esophagitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Eosinophilic Esophagitis market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of EoE, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Eosinophilic Esophagitis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Eosinophilic Esophagitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Eosinophilic Esophagitis market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Eosinophilic Esophagitis market

Report Highlights

  • In the coming years, the Eosinophilic Esophagitis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Eosinophilic Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for EoE. The launch of emerging therapies will significantly impact the EoE market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for EOE.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Eosinophilic Esophagitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Eosinophilic Esophagitis Pipeline Analysis
  • Eosinophilic Esophagitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Eosinophilic Esophagitis Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Eosinophilic Esophagitis Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Eosinophilic Esophagitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Eosinophilic Esophagitis Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Eosinophilic Esophagitis total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Eosinophilic Esophagitis market Size during the forecast period (2018–2030)?
  • At what CAGR, the Eosinophilic Esophagitis market is expected to grow in the 7MM during the forecast period (2018–2030)?
  • What would be the Eosinophilic Esophagitis market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Eosinophilic Esophagitis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Eosinophilic Esophagitis?
  • What is the historical Eosinophilic Esophagitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Eosinophilic Esophagitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Eosinophilic Esophagitis?
  • Out of all 7MM countries, which country would have the highest prevalence of Eosinophilic Esophagitis during the forecast period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Eosinophilic Esophagitis?
  • What are the current treatment guidelines for treating Eosinophilic Esophagitis in the USA, Europe, and Japan?
  • What are the Eosinophilic Esophagitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Eosinophilic Esophagitis?
  • How many therapies are developed by each company for the treatment of Eosinophilic Esophagitis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Eosinophilic Esophagitis?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Esophagitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Eosinophilic Esophagitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Eosinophilic Esophagitis?
  • What are the global historical and forecasted market for Eosinophilic Esophagitis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Eosinophilic Esophagitis market
  • To understand the future market competition in the Eosinophilic Esophagitis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic Esophagitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Eosinophilic Esophagitis market.
  • To understand the future market competition in the Eosinophilic Esophagitis market.

1. Key Insights

2. Report Introduction

3. Eosinophilic Esophagitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Eosinophilic Esophagitis in 2018

3.2. Market Share (%) Distribution of Eosinophilic Esophagitis in 2030

4. Eosinophilic Esophagitis Patient Split at a Glance

4.1. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2018

4.2. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2030

5. Executive Summary of Eosinophilic Esophagitis

6. Disease Background and Overview

6.1. Introduction

6.2. Clinical Manifestation

6.3. Risk factors associated with EoE

6.4. Phenotypes, Endotypes and Genotype correlation in Eosinophilic Esophagitis

6.5. Pathophysiology

6.6. Diagnosis

6.6.1. Differential Diagnosis

6.6.2. Complexities in EoE Diagnosis

7. Treatment

8. Guidelines for Management of EoE

8.1. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis

8.2. European statements and recommendations on the management of EoE

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. 7MM Total Diagnosed Prevalent Population of Eosinophilic Esophagitis

9.3. Epidemiology of Eosinophilic Esophagitis

9.4. The United States

9.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States

9.4.2. Gender-specific cases of Eosinophilic Esophagitis in the United States

9.4.3. Age-specific cases of Eosinophilic Esophagitis in the United States

9.5. EU5

9.5.1. Germany

9.5.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany

9.5.1.2. Gender-specific cases of Eosinophilic Esophagitis in Germany

9.5.1.3. Age-specific Cases of Eosinophilic Esophagitis in Germany

9.5.2. France

9.5.2.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in France

9.5.2.2. Gender-specific cases of Eosinophilic Esophagitis in France

9.5.2.3. Age-specific Cases of Eosinophilic Esophagitis in France

9.5.3. Italy

9.5.3.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy

9.5.3.2. Gender-specific cases of Eosinophilic Esophagitis in Italy

9.5.3.3. Age-specific Cases of Eosinophilic Esophagitis in Italy

9.5.4. Spain

9.5.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Spain

9.5.4.2. Gender-specific cases of Eosinophilic Esophagitis in Spain

9.5.4.3. Age-specific Cases of Eosinophilic Esophagitis in Spain

9.5.5. United Kingdom

9.5.5.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the UK

9.5.5.2. Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom

9.5.5.3. Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom

9.6. Japan

9.6.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan

9.6.1.2. Gender-specific cases of Eosinophilic Esophagitis in Japan

9.6.1.3. Age-specific Cases of Eosinophilic Esophagitis in Japan

10. Organizations contributing toward the fight against EoE

11. Patient Journey

12. Case Report

13. Marketed Drug

13.1. Jorveza: Dr Falk Pharma GmbH

13.2. Drug Description

13.3. Regulatory Milestone

13.4. Safety and Efficacy

13.5. Side Effect

13.6. Product Profile

14. Emerging Therapies

14.1. Key Cross Competition

14.2. Budesonide Oral Suspension: Takeda

14.2.1. Drug Description

14.2.2. Other Development Activities

14.2.3. Clinical Development

14.2.4. Clinical Trial Information

14.2.5. Safety and Efficacy

14.2.6. Product Profile

14.3. Dupilumab: Regeneron Pharmaceuticals/Sanofi

14.3.1. Drug Description

14.3.2. Other Development Activities

14.3.3. Clinical Development

14.3.4. Clinical Trial Information

14.3.5. Safety and Efficacy

14.3.6. Product Profile

14.4. Cendakimab: Bristol-Myers Squibb

14.4.1. Drug Description

14.4.2. Other Development Activities

14.4.3. Clinical Development

14.4.4. Clinical Trial Information

14.4.5. Safety and Efficacy

14.4.6. Product Profile

14.5. APT-1011: Ellodi Pharmaceuticals

14.5.1. Drug Description

14.5.2. Other Development Activities

14.5.3. Clinical Development

14.5.4. Clinical trial information

14.5.5. Safety and Efficacy

14.5.6. Product Profile

14.6. Benralizumab: AstraZeneca

14.6.1. Drug Description

14.6.2. Other Development Activities

14.6.3. Clinical Development

14.6.4. Clinical trial information

14.6.5. Product Profile

14.7. Lirentelimab: Allakos

14.7.1. Drug Description

14.7.2. Other Development Activities

14.7.3. Clinical Development

14.7.4. Clinical Trial Information

14.7.5. Safety and Efficacy

14.7.6. Product Profile

15. Other Promising Therapies

15.1. ESO-101: EsoCap AG

15.1.1. Drug Description

15.1.2. Other Development Activities

15.1.3. Clinical Development

15.1.4. Clinical trial information

15.1.5. Product Profile

15.2. Etrasimod: Arena Pharmaceutical

15.2.1. Drug Description

15.2.2. Other Development Activities

15.2.3. Clinical Development

15.2.4. Clinical Trial Information

15.2.5. Product Profile

15.3. Mepolizumab: GlaxoSmithKline

15.3.1. Drug Description

15.3.2. Clinical Development

15.3.3. Clinical Trial Information

15.3.4. Product Profile

16. Eosinophilic Esophagitis: 7 Major Market Analysis

16.1. Key Findings

16.2. Market Size of Eosinophilic Esophagitis in 7MM

16.3. Market Outlook

16.4. United States Market Size

16.4.1. Total Market Size of Eosinophilic Esophagitis in the United States

16.4.2. Market Size of Eosinophilic Esophagitis by Therapies in United States

16.4.3. Market Size of Eosinophilic Esophagitis by Class in the United States

16.5. EU-5 Market Size

16.5.1. Germany

16.5.1.1. Total Market size of Eosinophilic Esophagitis in Germany

16.5.1.2. Market Size of Eosinophilic Esophagitis by Therapies in Germany

16.5.1.3. Market Size of Eosinophilic Esophagitis by Class in Germany

16.5.2. France

16.5.2.1. Total Market size of Eosinophilic Esophagitis in France

16.5.2.2. Market Size of Eosinophilic Esophagitis by Therapies in France

16.5.2.3. Market Size of Eosinophilic Esophagitis by Class in France

16.5.3. Italy

16.5.3.1. Total Market size of Eosinophilic Esophagitis in Italy

16.5.3.2. Market Size of Eosinophilic Esophagitis by Therapies in Italy

16.5.3.3. Market Size of Eosinophilic Esophagitis by Class Italy

16.5.4. Spain

16.5.4.1. Total Market size of Eosinophilic Esophagitis in Spain

16.5.4.2. Market Size of Eosinophilic Esophagitis by Therapies in Spain

16.5.4.3. Market Size of Eosinophilic Esophagitis by Class in Spain

16.5.5. United Kingdom

16.5.5.1. Total Market size of Eosinophilic Esophagitis in United Kingdom

16.5.5.2. Market Size of Eosinophilic Esophagitis by Therapies in United Kingdom

16.5.5.3. Market Size of Eosinophilic Esophagitis by Class in the United Kingdom

16.6. Japan

16.6.1. Total Market size of Eosinophilic Esophagitis in Japan

16.6.2. Market Size of Eosinophilic Esophagitis by Therapies in Japan

16.6.3. Market Size of Eosinophilic Esophagitis by Class in Japan

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Summary of Eosinophilic Esophagitis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Clinical manifestations of EoE

Table 3: Risk factors of eosinophilic esophagitis

Table 4: Common risk genes with known functions

Table 5:  Eosinophilic Esophagitis Diagnostic Criteria

Table 6:  Diagnostic criteria for EoE proposed in Japan

Table 7: Endoscopic features of EoE

Table 8: New methods of diagnosis

Table 9: Conditions associated with Eosinophilic Esophagitis (EoE)

Table 10: Eosinophilic Esophagitis Treatment Summary

Table 11: GRADE Definitions on Strength of Recommendation

Table 12:  GRADE Definitions on Quality of Evidence

Table 13: American Gastroenterological Institute and Joint Task Force on Allergy-Immunology Practice Parameters Guideline Recommendations on the Management of Eosinophilic Esophagitis

Table 14: Knowledge and Evidence Gaps in the Management of Eosinophilic Esophagitis

Table 15: Summary of European Statements and recommendations on the management of EoE (Treatment) Table 16: Diagnosed Prevalence Population of Eosinophilic Esophagitis in 7MM (2018–2030)

Table 17: Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States (2018–2030)

Table 18: Gender-specific cases of Eosinophilic Esophagitis in the United States (2018–2030)

Table 19: Age-specific cases of Eosinophilic Esophagitis in the United States (2018–2030)

Table 20: Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany (2018–2030)

Table 21: Gender-specific cases of Eosinophilic Esophagitis in Germany (2018–2030)

Table 22: Age-specific Cases of Eosinophilic Esophagitis in Germany (2018–2030)

Table 23: Diagnosed prevalent cases of Eosinophilic Esophagitis in France (2018–2030)

Table 24: Gender-specific cases of Eosinophilic Esophagitis in France (2018–2030)

Table 25: Age-specific Cases of Eosinophilic Esophagitis in France (2018–2030)

Table 26: Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy (2018–2030)

Table 27: Gender-specific cases of Eosinophilic Esophagitis in Italy (2018–2030)

Table 28: Age-specific Cases of Eosinophilic Esophagitis in Italy (2018–2030)

Table 29: Diagnosed of Eosinophilic Esophagitis in Spain (2018–2030)

Table 30: Gender-specific cases of Eosinophilic Esophagitis in Spain (2018–2030)

Table 31: Age-specific Cases of Eosinophilic Esophagitis in Spain (2018–2030)

Table 32: Diagnosed prevalent cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Table 33: Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Table 34: Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Table 35: Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan (2018–2030)

Table 36: Gender-specific cases of Eosinophilic Esophagitis in Japan (2018–2030)

Table 37: Age-specific Cases of Eosinophilic Esophagitis in Japan (2018–2030)

Table 38:  Organizations contributing toward the fight against EOE

Table 39:  Budesonide Oral Suspension, Clinical Trial Description, 2021

Table 40:  Patent Description for Dupilumab

Table 41: Dupilumab, Clinical Trial Description, 2021

Table 42: Cendakimab, Clinical Trial Description, 2021

Table 43: APT-1011, Clinical Trial Description, 2021

Table 44: Benralizumab, Clinical Trial Description, 2021

Table 45:  Lirentelimab, Clinical Trial Description, 2021

Table 46: ESO-101, Clinical Trial Description, 2021

Table 47:  Etrasimod, Clinical Trial Description, 2021

Table 48: Mepolizumab, Clinical Trial Description, 2021

Table 49: Seven Major Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 50: The United States Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 51: The United States Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 52: The United States Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 53: Germany Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 54: Germany Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 55: Germany Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 56: France Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 57: France Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 58: France Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 59: Italy Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 60: Italy Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 61: Italy Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 62: Spain Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 63: Spain Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 64: Spain Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 65: United Kingdom Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 66: United Kingdom Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 67: The United Kingdom Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Table 68: Japan Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Table 69: Japan Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Table 70: Japan Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

List of Figures

Figure 1: Schematic overview of potential considerations in phenotype and endotype classification in eosinophilic esophagitis.

Figure 2: The proposed spectrum of EoE endotypes based on sIgG4 levels to Cow’s Milk (CM) proteins.

Figure 3: Genetic risks that may influence EoE endotype.

Figure 4: Overview of EoE Pathophysiology.

Figure 5: Pathophysiological overview of EoE

Figure 6: Eosinophilic Esophagitis Diagnostic Algorithm

Figure 7: Clinical, endoscopic, and histologic pitfalls in diagnosing EoE

Figure 8: Treatment of EoE

Figure 9: Therapeutic algorithm proposed for EoE in clinical practice

Figure 10: Diagnosed Prevalent Population of Eosinophilic Esophagitis in 7MM (2018–2030)

Figure 11: Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States (2018–2030)

Figure 12: Gender-specific cases of Eosinophilic Esophagitis in the United States (2018–2030)

Figure 13: Age-specific cases of Eosinophilic Esophagitis in the United States (2018–2030)

Figure 14: Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany (2018–2030)

Figure 15: Gender-specific cases of Eosinophilic Esophagitis in Germany (2018–2030)

Figure 16: Age-specific Cases of Eosinophilic Esophagitis in Germany (2018–2030)

Figure 17: Diagnosed prevalent cases of Eosinophilic Esophagitis in France (2018–2030)

Figure 18: Gender-specific cases of Eosinophilic Esophagitis in France (2018–2030)

Figure 19: Age-specific Cases of Eosinophilic Esophagitis in France (2018–2030)

Figure 20: Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy (2018–2030)

Figure 21: Gender-specific cases of Eosinophilic Esophagitis in Italy (2018–2030)

Figure 22: Age-specific Cases of Eosinophilic Esophagitis in Italy (2018–2030)

Figure 23: Diagnosed prevalent cases of Eosinophilic Esophagitis in Spain (2018–2030)

Figure 24: Gender-specific cases of Eosinophilic Esophagitis in Spain (2018–2030)

Figure 25: Age-specific Cases of Eosinophilic Esophagitis in Spain (2018–2030)

Figure 26: Diagnosed prevalent cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Figure 27: Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Figure 28: Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Figure 29: Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan (2018–2030)

Figure 30: Gender-specific cases of Eosinophilic Esophagitis in Japan (2018–2030)

Figure 31: Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom (2018–2030)

Figure 32: Seven Major Market Size of Eosinophilic Esophagitis in USD Million (2018–2030)

Figure 33: Market Size of Eosinophilic Esophagitis in the United States, USD Million (2018–2030)

Figure 34: The United States Market Size of Eosinophilic Esophagitis by Therapies in USD Million

Figure 35: The United States Market Size of Eosinophilic Esophagitis by Class in USD Million

Figure 36: Market Size of Eosinophilic Esophagitis in Germany, USD Million (2018–2030)

Figure 37: Germany Market Size of Eosinophilic Esophagitis by Therapies in USD Million

Figure 38: Germany Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Figure 39: Market Size of Eosinophilic Esophagitis in France, USD Million (2018–2030)

Figure 40: France Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Figure 41: France Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Figure 42: Market Size of Eosinophilic Esophagitis in Italy, USD Million (2018–2030)

Figure 43: Italy Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Figure 44: Italy Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Figure 45: Market Size of Eosinophilic Esophagitis in Spain, USD Million (2018–2030)

Figure 46: Spain Market Size of Eosinophilic Esophagitis by Therapies in USD Million (2018–2030)

Figure 47: Spain Market Size of Eosinophilic Esophagitis by Class in USD Million (2018–2030)

Figure 48: Market Size of Eosinophilic Esophagitis in the United Kingdom, USD Million (2018–2030)

Figure 49: The United Kingdom Market Size of Eosinophilic Esophagitis by Therapies in USD Million

Figure 50: The United Kingdom Market Size of Eosinophilic Esophagitis by Class in USD Million

Figure 51: Market Size of Eosinophilic Esophagitis in Japan, USD Million (2018–2030)

Figure 52: Japan Market Size of Eosinophilic Esophagitis by Therapies in USD Million

Figure 53: Japan Market Size of Eosinophilic Esophagitis by Class in USD Million

Jorveza: Dr Falk Pharma GmbH

Budesonide Oral Suspension: Takeda

Dupilumab: Regeneron Pharmaceuticals/Sanofi

Cendakimab: Bristol-Myers Squibb

APT-1011: Ellodi Pharmaceuticals

Benralizumab: AstraZeneca

Lirentelimab: Allakos

ESO-101: EsoCap AG

Etrasimod: Arena Pharmaceutical

Mepolizumab: GlaxoSmithKline

  • Tags:
  • Eosinophilic Esophagitis market
  • Eosinophilic Esophagitis market re...
  • Eosinophilic Esophagitis market in...
  • Eosinophilic Esophagitis market tr...
  • Eosinophilic Esophagitis market fo...
  • Eosinophilic Esophagitis market sh...
  • Eosinophilic Esophagitis pipeline...
  • Eosinophilic Esophagitis treatment...
  • Eosinophilic Esophagitis drugs
  • Eosinophilic Esophagitis sales for...
  • Eosinophilic Esophagitis market si...
  • Eosinophilic Esophagitis disease
  • Eosinophilic Esophagitis epidemiol...
  • Eosinophilic Esophagitis

Forward to Friend

Need A Quote